Published in PLoS One on February 06, 2015
MicroRNA-27b, microRNA-101 and microRNA-128 inhibit angiogenesis by down-regulating vascular endothelial growth factor C expression in gastric cancers. Oncotarget (2015) 0.94
microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1. BMC Cancer (2015) 0.84
Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2. Oncotarget (2016) 0.82
Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy. J Exp Clin Cancer Res (2016) 0.82
miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinoma. Oncotarget (2016) 0.80
The role of microRNAs in bladder cancer. Investig Clin Urol (2016) 0.79
MicroRNA-101 has a suppressive role in osteosarcoma cells through the targeting of c-FOS. Exp Ther Med (2016) 0.79
MicroRNA-101 inhibits proliferation, migration and invasion in osteosarcoma cells by targeting ROCK1. Am J Cancer Res (2017) 0.78
ODAM is a predictor for biomedical recurrence and inhibits the migration and invasion of prostate cancer. Am J Transl Res (2016) 0.77
MicroRNA-101 regulates the viability and invasion of cervical cancer cells. Int J Clin Exp Pathol (2015) 0.75
The prognostic value of decreased miR-101 in various cancers: a meta-analysis of 12 studies. Onco Targets Ther (2017) 0.75
Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets. Int J Mol Sci (2017) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
Lymphangiogenesis: Molecular mechanisms and future promise. Cell (2010) 5.84
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
The microcosmos of cancer. Nature (2012) 4.50
MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res (2009) 3.83
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res (2009) 2.83
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell (2006) 2.13
MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer (2010) 2.08
Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res (1999) 2.03
Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer (1999) 1.87
High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res (2000) 1.85
Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer (2000) 1.67
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol (1998) 1.61
Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol (2001) 1.58
FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell (2011) 1.49
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol (2010) 1.35
Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer (2012) 1.30
MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J Hepatol (2013) 1.22
Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21
miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep (2013) 1.18
MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance. Med Oncol (2011) 1.18
MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One (2012) 1.17
Update on chemotherapy for advanced bladder cancer. J Urol (2005) 1.15
Reference miRNAs for miRNAome analysis of urothelial carcinomas. PLoS One (2012) 1.09
miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics (2012) 1.08
MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck (2010) 1.06
Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther (2012) 1.04
Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol (2003) 1.04
Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol (2005) 1.03
MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun (2013) 1.00
VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia (2014) 0.99
miR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinoma. Biomed Rep (2013) 0.99
MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep (2014) 0.98
Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery (1999) 0.95
MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett (2013) 0.94
VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer (2014) 0.94
Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc Natl Acad Sci U S A (2013) 0.90
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int (2008) 0.90
The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis. BJU Int (2008) 0.88
The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer. BJU Int (2006) 0.87
Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas. Int J Clin Oncol (2010) 0.87
Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer (2003) 0.86
Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. Cancer Lett (2013) 0.86
Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology (2008) 0.79
Role of lymphadenectomy for invasive bladder cancer. Can Urol Assoc J (2009) 0.77